Tone mix
Week by week 52 weeks
Share of Spero Therapeutics, Inc. Common Stock's 96 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jan 5, 2026 · tone -100Spero Therapeutics (NASDAQ:SPRO) Cut to "Hold" at Wall Street Zen-163
- Week of Sep 16, 2024 · tone -100Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving Average of $1.48-128
- Week of Sep 23, 2024 · tone -100Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average of $1.46-125
- Week of Jan 27, 2025 · tone +100Spero Therapeutics (NASDAQ:SPRO) Receives "Buy" Rating from HC Wainwright+99
- Week of Dec 16, 2024 · tone -96Evercore ISI Downgrades Spero Therapeutics (NASDAQ:SPRO) to In-Line-80
- Week of Jul 27, 2026 · tone 0Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer-75
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Spero Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | -1 |
| Last 30 sessions | 9 | +21 |
| Last 90 sessions | 30 | +33 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, November 5, 2026
1 headline, average tone +97: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
1 headline, average tone -100: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.tickerreport.com · 1 outletSpero Therapeutics (NASDAQ:SPRO) Rating Lowered to "Sell" at Wall Street ZenNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spero Therapeutics (NASDAQ:SPRO) Rating Lowered to "Sell" at Wall Street Zen | www.tickerreport.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone +95: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletSpero Therapeutics Strengthens Leadership Team to Advance Immunology PipelinePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +94: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletSpero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related DiseasePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.tickerreport.com · 1 outletAnalyzing Kiora Pharmaceuticals (NASDAQ:KPRX) & Spero Therapeutics (NASDAQ:SPRO)Neutral
- www.dailypolitical.com · 1 outletHead to Head Analysis: Kiora Pharmaceuticals (NASDAQ:KPRX) versus Spero Therapeutics (NASDAQ:SPRO)Neutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analyzing Kiora Pharmaceuticals (NASDAQ:KPRX) & Spero Therapeutics (NASDAQ:SPRO) | www.tickerreport.com | 1 | Neutral |
| Head to Head Analysis: Kiora Pharmaceuticals (NASDAQ:KPRX) versus Spero Therapeutics (NASDAQ:SPRO) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Spero Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.